

Key Figures of Consolidated Financial Results for 2nd Quarter (Interim Period) FY2025

November 4th, 2025
Sumitomo Chemical Co., Ltd.

(Billions of yen)

1. Financial Summary (IFRS)

	Q2 FY2025	Q2 FY2024	Variance	FY2025 (Revised Forecast announced in Nov.)	FY2024
Sales revenue	1,095.4	1,241.4	(146.0)	2,290.0	2,606.3
Core operating income	108.7	29.5	79.2	185.0	140.5
Operating income	103.7	121.2	(17.6)	160.0	193.0
Net income (loss) attributable to owners of the parent	39.7	(6.5)	46.2	45.0	38.6
Basic earnings (loss) per share	¥ 24.26	¥ (3.99)	¥ 28.25	¥ 27.50	¥23.59
Return on equity	4.3%	(0.7)%	5.0%	4.9%	4.1%
Exchange rate (yen/\$)	146.02	152.78	—	145.51 (2nd Half 145.00)	152.62
Naphtha price (yen/kl)	64,900	78,000	—	64,200 (2nd Half 63,500)	75,600

*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

2. Sales Revenue / Core Operating Income by Reportable Segment (IFRS)

(Billions of yen)

		Q2 FY2025	Q2 FY2024	Variance	FY2025 (Revised Forecast announced in Nov.)	FY2024
Agro & Life Solutions	Sales revenue	213.0	225.0	(12.0)	530.0	540.2
	Core operating income	11.2	14.2	(2.9)	55.0	55.0
ICT & Mobility Solutions	Sales revenue	283.5	307.5	(24.0)	550.0	607.0
	Core operating income	33.1	43.6	(10.5)	53.0	70.6
Advanced Medical Solutions	Sales revenue	21.1	26.8	(5.6)	60.0	62.1
	Core operating income	(1.4)	0.4	(1.7)	4.0	4.0
Essential & Green Materials	Sales revenue	329.1	450.9	(121.8)	680.0	899.0
	Core operating income	(18.6)	(34.8)	16.1	13.0	(58.5)
Sumitomo Pharma	Sales revenue	226.1	180.4	45.7	420.0	398.0
	Core operating income	97.3	3.0	94.3	100.0	35.3
Others	Sales revenue	22.6	50.8	(28.3)	50.0	99.9
	Core operating income	3.2	19.4	(16.2)	5.0	66.9
Adjustments	Sales revenue	—	—	—	—	—
	Core operating income	(16.2)	(16.3)	0.1	(45.0)	(32.7)
Total	Sales revenue	1,095.4	1,241.4	(146.0)	2,290.0	2,606.3
	Core operating income	108.7	29.5	79.2	185.0	140.5

*The Group changed its reportable segments from Q3 FY2024. The segment information for Q2 FY2024 has been reclassified to reflect the change in the reportable segments.

3. Summary of Consolidated Statement of Income (IFRS)

(Billions of yen)

	Q2 FY2025	Q2 FY2024	Variance	Variance Ratio
Sales revenue	1,095.4	1,241.4	(146.0)	(11.8)%
Core operating income	108.7	29.5	79.2	268.8%
Of which equity in earnings	(27.3)	(33.6)	6.2	—
Total non-recurring items	(5.0)	91.8	(96.8)	—
Of which restructuring costs	(3.5)	(11.7)	8.2	—
Of which impairment losses	(3.3)	(0.3)	(3.0)	—
Of which gains on sales of property, plant and equipment, and intangible assets	0.2	10.7	(10.5)	—
Of which share of profit of investments accounted for using the equity method (non-recurring factors)	—	86.5	(86.5)	—
Of which gains on fair value measurement of the residual interest	—	9.4	(9.4)	—
Others	1.6	(2.9)	4.5	—
Operating income	103.7	121.2	(17.6)	(14.5)%
Finance income/expenses	(15.8)	(151.8)	136.0	—
Of which (loss) on foreign currency transactions including gain (loss) on derivatives	(6.4)	(34.8)	28.4	—
Of which loss on debt waiver for a loan	—	(109.8)	109.8	—
Others	(9.4)	(7.2)	(2.2)	—
Income (loss) before taxes	87.9	(30.5)	118.4	—
Income tax expenses	3.0	10.3	(7.2)	—
Net income (loss)	90.9	(20.3)	111.2	—
Net (income) loss attributable to non-controlling interests	(51.2)	13.8	(65.0)	—
Net income (loss) attributable to owners of the parent	39.7	(6.5)	46.2	—
ROE	4.3%	(0.7)%		
Exchange rate (yen/\$)	146.02	152.78		
Naphtha price (yen/kl)	64,900	78,000		
Overseas sales revenue ratio	70.0%	69.0%		

4. Summary of Consolidated Statement of Financial Position (IFRS)

(Billions of yen)

	30-Sep-25	31-Mar-25	Variance		30-Sep-25	31-Mar-25	Variance
Current Assets	1,577.5	1,583.1	(5.6)	Liabilities	2,184.9	2,365.4	(180.5)
Cash and cash equivalents	161.2	209.8	(48.6)	Trade and other payables	478.3	488.1	(9.8)
Trade and other receivables	581.5	593.8	(12.4)	Interest-bearing liabilities	1,191.7	1,286.1	(94.5)
Inventories	643.7	625.2	18.5	Others	514.9	591.1	(76.2)
Others	191.1	154.2	36.9	Equity	1,179.6	1,074.4	105.2
Non-current assets	1,787.0	1,856.7	(69.7)	Shareholders' equity	738.5	722.3	16.2
Property, plant and equipment	764.4	759.3	5.1	Other components of equity	220.2	178.5	41.7
Goodwill and intangible assets	489.0	497.1	(8.2)	Non-controlling interests	220.9	173.6	47.3
Others	533.6	600.3	(66.6)				
Total	3,364.5	3,439.8	(75.3)	Total	3,364.5	3,439.8	(75.3)
				Ratio of equity attributable to owners of the parent to total assets	28.5%	26.2%	2.3%
				D/E ratio (times)	1.01	1.20	(0.19)

5. Summary of Consolidated Statement of Cash Flows (IFRS)

	Q2 FY2025	Q2 FY2024	Variance	(Billions of yen) FY2024
Cash flows from operating activities	57.7	63.5	(5.9)	233.0
Cash flows from investing activities	(16.7)	74.4	(91.1)	85.2
Free cash flows	41.0	138.0	(97.0)	318.3
Cash flows from financing activities	(114.8)	(75.4)	(39.4)	(300.8)
Others	2.9	(7.9)	10.8	(6.8)
Increase (decrease) in cash and cash equivalents	(70.9)	54.7	(125.6)	10.7
Cash and cash equivalents at the end of the period	161.2	273.4	(112.1)	209.8



November 4, 2025

Summary of Consolidated Financial Results for Second Quarter (Interim Period) Fiscal Year 2025 (Under IFRS)

Company name: Sumitomo Chemical Co., Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 4005
 URL: <https://www.sumitomo-chem.co.jp/english/>
 Representative: Nobuaki Mito, Representative Director & President
 Inquiries: Shunji Kobayashi, General Manager, Corporate Communications Dept.
 Telephone: +81-3-5201-0200

Scheduled date to commence dividend payments: December 2, 2025
 Scheduled date to file semi-annual securities report: November 10, 2025
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for institutional investors and analysts)

(All amounts are rounded to the nearest million yen.)

1. Consolidated Financial Results for Second Quarter (Interim Period) Fiscal Year 2025 (April 1, 2025 to September 30, 2025)

(1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Sales revenue		Core operating income		Operating income		Net income		Net income attributable to owners of the parent		Total comprehensive income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Q2 FY2025	1,095,394	(11.8)	108,716	268.8	103,685	(14.5)	90,929	—	39,699	—	119,446	—
Q2 FY2024	1,241,395	4.6	29,476	—	121,249	—	(20,285)	—	(6,527)	—	(70,432)	—

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Q2 FY2025	24.26	24.25
Q2 FY2024	(3.99)	—

Reference: Share of profit or loss of investments accounted for using the equity method

Q2 FY2025: ¥ (27,339) million Q2 FY2024: ¥ 52,934 million

Income before taxes

Q2 FY2025: ¥ 87,898 million Q2 FY2024: ¥ (30,539) million

*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

*For diluted earnings per share for Q2 FY2024, although there are potential shares, they are not listed because they have an anti-dilutive effect.

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
September 30, 2025	3,364,498	1,179,642	958,739	28.5
March 31, 2025	3,439,784	1,074,415	900,790	26.2

2. Dividends

	Dividends per share				
	1st quarter end	2nd quarter end	3rd quarter end	Year-end	Annual
	Yen	Yen	Yen	Yen	Yen
FY2024	—	3.00	—	6.00	9.00
FY2025	—	6.00			
FY2025 (Forecast)			—	6.00	12.00

Note: Revision of dividend forecasts from the latest announcement: None

3. Consolidated Financial Forecasts for Fiscal Year 2025

(April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Sales revenue		Core operating income		Operating income		Net income attributable to owners of the parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full-year of FY2025	2,290,000	(12.1)	185,000	31.7	160,000	(17.1)	45,000	16.6	27.50

Note: Revision of financial forecasts from the latest announcement: Yes

Notes:

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: —

Excluded: 1 company (XUYOU Electronic Materials (Wuxi) Co., Ltd.)

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(3) Number of shares issued (common shares)

(i) Total number of shares issued at the end of the period (including treasury shares)

As of September 30, 2025	1,657,914,399 shares
As of March 31, 2025	1,657,217,608 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2025	20,521,696 shares
As of March 31, 2025	20,517,033 shares

(iii) Average number of shares outstanding during the period

Six Months ended September 30, 2025	1,636,596,564 shares
Six Months ended September 30, 2024	1,635,844,492 shares

*This summary of financial results is exempt from audit procedures.

*Notes to appropriate use of forecasts and other special items:

Descriptions regarding forward-looking statements about the future performance of the Company contained in this summary are based on information currently available to the Company and certain assumptions judged reasonable and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in the Company's markets; demand for, and competitive pricing pressure on, the Company's products in the marketplace; rise in prices of raw materials; and fluctuations in foreign exchange rates.

*This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Attachments

1. Summary of Operating Results	
for Second Quarter (Interim Period) Fiscal Year 2025	2
(1) Operating Results	2
(2) Consolidated Financial Position	3
(3) Consolidated Forecast and Other Forward-Looking Information	3
2. Consolidated Financial Statements and Major Notes	5
(1) Consolidated Statement of Financial Position	5
(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income	7
(3) Consolidated Statement of Changes in Equity	9
(4) Consolidated Statement of Cash Flows	11
(5) Notes to Consolidated Financial Statements	12
(Going Concern Assumption)	12
(Segment Information)	12
(Material Subsequent Events)	14

1. Summary of Operating Results for Second Quarter (Interim Period) Fiscal Year 2025

(1) Operating Results

For Q2 FY2025, the Group's sales revenue decreased by ¥146.0 billion compared to Q2 FY2024, to ¥1,095.4 billion. In terms of profits and losses, core operating income* was ¥108.7 billion, higher than in Q2 FY2024. Operating income was ¥103.7 billion, lower than in Q2 FY2024, but net income attributable to owners of the parent was ¥39.7 billion, higher than in Q2 FY2024.

The company decided to pay an interim dividend of ¥6 per share.

*Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

The financial results by reportable segment for Q2 FY2025 are as follows:

Agro & Life Solutions

While shipments of crop protection products in India and elsewhere were strong, market conditions in South America deteriorated. Compared to Q2 FY2024, market conditions for methionine (feed additive) deteriorated, and shipments declined. Further, the stronger yen also had a negative effect on sales from subsidiaries outside of Japan when converted into yen. As a result, sales revenue decreased by ¥12.0 billion compared to Q2 FY2024, to ¥213.0 billion. Core operating income was ¥11.2 billion, down by ¥2.9 billion from Q2 FY2024.

ICT & Mobility Solutions

Market inventory adjustments and changes in the timing of demand led to a decline in shipments of both display-related materials and high-purity chemicals and photoresists used in the semiconductor manufacturing process. The stronger yen decreased income from exports and had a negative effect on sales from subsidiaries outside of Japan in yen terms. Results were also impacted by fundamental structural reforms implemented for the polarizing film business for large-size liquid crystal displays. As a result, sales revenue declined by ¥24.0 billion compared to Q2 FY2024, to ¥283.5 billion, and core operating income declined by ¥10.5 billion from Q2 FY2024, to ¥33.1 billion.

Advanced Medical Solutions

Shipments of active pharmaceutical ingredients and intermediates decreased because the timing of shipments for some products differed from Q2 FY2024. As a result, sales revenue decreased by ¥5.6 billion from Q2 FY2024, to ¥21.1 billion, and core operating income posted a loss of ¥1.4 billion, a decline in income of ¥1.7 billion from Q2 FY2024.

Essential & Green Materials

Shipments of the sales subsidiary declined, because of the periodic shutdown maintenance at Rabigh Refining and Petrochemical Company (hereinafter, "Petro Rabigh"), an affiliated company accounted for using the equity method. In addition, shipments of aluminum and other products decreased due to the Group's exit from the business in FY2024. As a result, sales revenue decreased by ¥121.8 billion from Q2 FY2024, to ¥329.1 billion. Core operating income posted a loss of ¥18.6 billion, improved by ¥16.1 billion from Q2 FY2024, due to an improvement in the terms of trade for Petro Rabigh and for synthetic resins and other products.

Sumitomo Pharma

Sales revenue declined in Japan and Asia, but in North America, there was an increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (therapeutic agent for overactive bladder). Sales revenue was further increased by the recording of an ORGOVYX® sales milestone. As a result, sales revenue increased by ¥45.7 billion from Q2 FY2024, to ¥226.1 billion. Core operating income was ¥97.3 billion, an increase of ¥94.3 billion from Q2 FY2024. In addition to the benefit of higher sales revenue, there was a significant reduction in selling, general and administrative expenses, including research and development expenses, resulting from the effects of business structure improvements, and there was also a gain posted on the partial divestiture of the Asian business. Sales revenue and core operating income differ between this segment and the results reported by Sumitomo Pharma, Co., Ltd., a subsidiary of Sumitomo Chemical Co., Ltd., due to the Group's contract development and manufacturing organization business for regenerative medicine and cell therapy products not being included in this segment and because of the Group's consolidated account reporting.

Others

In addition to the above five segments, the Group supplies electric power and steam, and also provides transportation and warehousing. Sales revenue decreased by ¥28.3 billion from Q2 FY2024, to ¥22.6 billion, due to the sale of the radiopharmaceutical business and other businesses in FY2024. Core operating income decreased by ¥16.2 billion from Q2 FY2024, to ¥3.2 billion, also because Sumitomo Bakelite Co., Ltd. is no longer accounted for using the equity method, following a partial transfer of shares in FY2024.

(2) Consolidated Financial Position

As of the end of Q2 FY2025, total assets decreased by ¥75.3 billion compared to the end of FY2024, to ¥3,364.5 billion. Cash and cash equivalents as well as trade and other receivables decreased.

Total liabilities decreased by ¥180.5 billion compared to the end of FY2024, to ¥2,184.9 billion. Interest-bearing liabilities decreased by ¥94.5 billion compared to the end of FY2024, to ¥1,191.7 billion.

Total equity (including non-controlling interests) increased by ¥105.2 billion compared to the end of FY2024, to ¥1,179.6 billion, because of increases in non-controlling interests and other components of equity.

The ratio of equity attributable to the owners of the parent to total assets increased by 2.3 percentage points compared to the end of FY2024, to 28.5%.

(3) Consolidated Forecast and Other Forward-Looking Information

Based on recent performance trends, the Company has made revisions to its consolidated financial forecast for the full year ending March 31, 2026, previously announced on May 14, 2025, as detailed below.

Revisions to Consolidated Financial Forecast for the Full Year Ending March 31, 2026 (April 1, 2025 – March 31, 2026)

(Millions of yen)					
	Sales Revenue	Core Operating Income	Operating Income	Net Income Attributable to Owners of the Parent	Earnings per Share (yen)
Previous forecast (A)	2,340,000	150,000	105,000	40,000	24.44
Revised forecast (B)	2,290,000	185,000	160,000	45,000	27.50
Variance in amount (B-A)	(50,000)	35,000	55,000	5,000	
Variance in percentage (%)	(2.1%)	23.3%	52.4%	12.5%	
Results for the full year ended March 31, 2025	2,606,281	140,519	193,033	38,591	23.59

Reasons for the Revision

Regarding the forecast for the full fiscal year ending March 31, 2026, in the Essential & Green Materials Chemicals segment, the Company anticipates a decline in sales revenue from the previous forecast due to decreased shipments of synthetic resins. On the other hand, in the Sumitomo Pharma segment, the Company anticipates that sales in North America will continue to be strong. Due to these factors, core operating income, operating income, and net income attributable to owners of the parent are expected to exceed the previous forecast. Regarding the partial sale of shares in Petro Rabigh, the Company has incorporated the impact on the profits and losses at each phase. For more information, please see the Company's press release "(Progress of Disclosure Matters) Notice Regarding the Recording of Gain on Sale of a Portion of the Class A* Ordinary Shares Sumitomo Chemical Holds in Petro Rabigh, and Associate Accounted for Using the Equity Method and Loss on Valuation of Newly Acquired Petro Rabigh Class B** Ordinary Shares in Consolidated Financial Statements, and Extraordinary Losses in Non-Consolidated Financial Statements Pertaining to the Class B Ordinary Shares," which was published on October 22, 2025.

The revised forecast is based on information currently available, and actual performance may vary due to various factors in the future.

(Note 1): Class A ordinary shares refer to ordinary shares with voting rights, and as a result of the issuance of the new Class B ordinary shares, the name of the existing ordinary shares was changed to Class A ordinary shares.

(Note 2): Class B ordinary shares have no voting rights, and certain dividends rights are granted at varying rates each year from 2028 onwards.

(Supplemental information)

Consolidated Financial Forecast by Segment for the Full Year Ending March 31, 2026

(Millions of yen)

		FY2025 Previous Forecast (A)	FY2025 Revised Forecast (B)	Variance in Amount (B-A)
Agro & Life Solutions	Sales revenue	530,000	530,000	-
	Core operating income	55,000	55,000	-
ICT & Mobility Solutions	Sales revenue	580,000	550,000	(30,000)
	Core operating income	56,000	53,000	(3,000)
Advanced Medical Solutions	Sales revenue	60,000	60,000	-
	Core operating income	4,000	4,000	-
Essential & Green Materials	Sales revenue	780,000	680,000	(100,000)
	Core operating income	(10,000)	13,000	23,000
Sumitomo Pharma	Sales revenue	350,000	420,000	70,000
	Core operating income	59,000	100,000	41,000
Others & Adjustments	Sales revenue	40,000	50,000	10,000
	Core operating income	(14,000)	(40,000)	(26,000)
Total	Sales revenue	2,340,000	2,290,000	(50,000)
	Core operating income	150,000	185,000	35,000

2. Consolidated Financial Statements and Major Notes

(1) Consolidated Statement of Financial Position

Millions of yen	As of September 30, 2025		As of March 31, 2025	
Assets				
Current assets:				
Cash and cash equivalents	¥	161,209	¥	209,838
Trade and other receivables		581,477		593,836
Other financial assets		55,154		45,015
Inventories		643,721		625,243
Other current assets		56,775		49,993
Subtotal		1,498,336		1,523,925
Assets held for sale		79,169		59,209
Total current assets		1,577,505		1,583,134
Non-current assets:				
Property, plant and equipment		764,399		759,266
Goodwill		257,782		257,811
Intangible assets		231,174		239,319
Investments accounted for using the equity method		197,730		287,977
Other financial assets		196,200		177,405
Retirement benefit assets		73,450		72,618
Deferred tax assets		38,694		34,608
Other non-current assets		27,564		27,646
Total non-current assets		1,786,993		1,856,650
Total assets	¥	3,364,498	¥	3,439,784

Liabilities and equity**Liabilities**

Current liabilities:

Bonds and borrowings	¥	197,406	¥	252,892
Trade and other payables		478,325		488,132
Other financial liabilities		53,058		81,364
Income taxes payable		10,474		10,627
Provisions		90,224		89,711
Other current liabilities		103,141		109,360
Subtotal		932,628		1,032,086
Liabilities directly associated with assets held for sale		—		6,661
Total current liabilities		932,628		1,038,747
Non-current liabilities:				
Bonds and borrowings		994,262		1,033,236
Other financial liabilities		88,720		91,157
Retirement benefit liabilities		23,610		24,841
Provisions		27,380		25,974
Deferred tax liabilities		91,651		111,048
Other non-current liabilities		26,605		40,366
Total non-current liabilities		1,252,228		1,326,622
Total liabilities		2,184,856		2,365,369

Equity

Share capital		90,179		90,059
Capital surplus		120		—
Retained earnings		656,574		640,611
Treasury shares		(8,362)		(8,361)
Other components of equity		206,928		174,871
Other comprehensive income associated with assets held for sale		13,300		3,610
Equity attributable to owners of the parent		958,739		900,790
Non-controlling interests		220,903		173,625
Total equity		1,179,642		1,074,415
Total liabilities and equity	¥	3,364,498	¥	3,439,784

(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income

Consolidated Statement of Income

Second Quarter (Interim Period) ended September 30, 2025 and 2024

Millions of yen	Q2 FY2025		Q2 FY2024	
Sales revenue	¥	1,095,394	¥	1,241,395
Cost of sales		(749,314)		(891,218)
Gross profit		346,080		350,177
Selling, general and administrative expenses		(273,398)		(300,290)
Other operating income		66,703		36,071
Other operating expenses		(8,361)		(17,643)
Share of profit (loss) of investments accounted for using the equity method		(27,339)		52,934
Operating income		103,685		121,249
Finance income		7,105		12,283
Finance expenses		(22,892)		(164,071)
Income before taxes (loss)		87,898		(30,539)
Income tax expenses		3,031		10,254
Net income (loss)		90,929		(20,285)
Net income (loss) attributable to:				
Owners of the parent		39,699		(6,527)
Non-controlling interests		51,230		(13,758)
Net income (loss)	¥	90,929	¥	(20,285)

Yen	Q2 FY2025	Q2 FY2024
Earnings per share:		
Basic earnings (loss) per share	24.26	(3.99)
Diluted earnings per share	24.25	—

Consolidated Statement of Comprehensive Income

Second Quarter (Interim Period) ended September 30, 2025 and 2024

Millions of yen	Q2 FY2025		Q2 FY2024	
Net income (loss)	¥	90,929	¥	(20,285)
Other comprehensive income:				
Items that will not be reclassified to profit or loss				
Remeasurements of financial assets (equity instruments) measured at fair value through other comprehensive income		17,850		(21,477)
Remeasurements of defined benefit plans		249		(105)
Share of other comprehensive income of investments accounted for using the equity method		1,766		1,764
Total items that will not be reclassified to profit or loss		19,865		(19,818)
Items that may be subsequently reclassified to profit or loss				
Remeasurements of financial assets (debt instruments) measured at fair value through other comprehensive income		58		(74)
Cash flow hedges		(114)		(105)
Exchange differences on conversion of foreign operations		12,564		(38,124)
Share of other comprehensive income of investments accounted for using the equity method		(3,856)		7,974
Total items that may be subsequently reclassified to profit or loss		8,652		(30,329)
Other comprehensive income, net of taxes		28,517		(50,147)
Total comprehensive income		119,446		(70,432)
Total comprehensive income attributable to:				
Owners of the parent		67,530		(51,297)
Non-controlling interests		51,916		(19,135)
Total comprehensive income	¥	119,446	¥	(70,432)

(3) Consolidated Statement of Changes in Equity

Second Quarter (Interim Period) ended September 30, 2025

	Equity attributable to owners of the parent						Other components of equity	
	Share capital	Capital surplus	Retained earnings	Treasury shares			Remeasurements of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Millions of yen								
Balance as of April 1, 2025	¥ 90,059	¥ —	¥ 640,611	¥ (8,361)			¥ 1,186	¥ —
Net income (loss)	—	—	39,699	—			—	—
Other comprehensive income	—	—	—	—			17,351	268
Total comprehensive income	—	—	39,699	—			17,351	268
Issuance of new shares	120	120	—	—			—	—
Purchase of treasury shares	—	—	—	(2)			—	—
Disposal of treasury shares	—	(0)	—	0			—	—
Dividends	—	—	(9,820)	—			—	—
Changes resulting from loss of control of subsidiaries	—	—	1,789	—			(1,611)	(221)
Changes in interest due to transactions with non-controlling interests	—	—	—	—			—	—
Transfer from other components of equity to retained earnings	—	—	(15,705)	—			15,752	(47)
Transfer to other comprehensive income associated with assets held for sale	—	—	—	—			—	—
Total transactions with owners	120	120	(23,736)	(2)			14,141	(268)
Balance as of September 30, 2025	¥ 90,179	¥ 120	¥ 656,574	¥ (8,362)			¥ 32,678	¥ —

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Other components of equity			Other comprehensive income associated with assets held for sale	Equity attributable to owners of the parent			
	Cash flow hedges	Exchange differences on conversion of foreign operations	Total					
Balance as of April 1, 2025	¥	87	¥ 173,598	¥ 174,871	¥ 3,610	¥ 900,790	¥ 173,625	¥1,074,415
Net income (loss)		—	—	—	—	39,699	51,230	90,929
Other comprehensive income		(78)	15,572	33,113	(5,282)	27,831	686	28,517
Total comprehensive income		(78)	15,572	33,113	(5,282)	67,530	51,916	119,446
Issuance of new shares		—	—	—	—	240	—	240
Purchase of treasury shares		—	—	—	—	(2)	—	(2)
Disposal of treasury shares		—	—	—	—	0	—	0
Dividends		—	—	—	—	(9,820)	(1,471)	(11,291)
Changes resulting from loss of control of subsidiaries		—	—	(1,832)	43	—	(3,176)	(3,176)
Changes in interest due to transactions with non-controlling interests		—	—	—	—	—	9	9
Transfer from other components of equity to retained earnings		—	—	15,705	—	—	—	—
Transfer to other comprehensive income associated with assets held for sale		—	(14,929)	(14,929)	14,929	—	—	—
Total transactions with owners		—	(14,929)	(1,056)	14,972	(9,582)	(4,638)	(14,220)
Balance as of September 30, 2025	¥	9	¥ 174,241	¥ 206,928	¥ 13,300	¥ 958,739	¥ 220,903	¥1,179,642

Second Quarter (Interim Period) ended September 30, 2024

	Equity attributable to owners of the parent											
					Other components of equity							
	Share capital		Capital surplus		Retained earnings		Treasury shares		Remeasurements of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans		
Millions of yen												
Balance as of April 1, 2024	¥	89,938	¥	237	¥	578,175	¥	(8,355)	¥	83,448	¥	—
Net income (loss)		—		—		(6,527)		—		—		—
Other comprehensive income		—		—		—		—		(15,298)		181
Total comprehensive income		—		—		(6,527)		—		(15,298)		181
Issuance of new shares		120		120		—		—		—		—
Purchase of treasury shares		—		—		—		(3)		—		—
Disposal of treasury shares		—		(0)		—		0		—		—
Dividends		—		—		(4,908)		—		—		—
Changes resulting from loss of control of subsidiaries		—		—		—		—		—		—
Changes in interest due to transactions with non-controlling interests		—		(35)		—		—		—		—
Transfer from other components of equity to retained earnings		—		—		34,603		—		(34,422)		(181)
Transfer to other comprehensive income associated with assets held for sale		—		—		—		—		—		—
Total transactions with owners		120		85		29,695		(3)		(34,422)		(181)
Balance as of September 30, 2024	¥	90,059	¥	322	¥	601,343	¥	(8,358)	¥	33,728	¥	—

	Equity attributable to owners of the parent						
	Other components of equity			Other comprehensive income associated with assets held for sale	Equity attributable to owners of the parent	Non-controlling interests	Total equity
	Cash flow hedges	Exchange differences on conversion of foreign operations	Total				
Balance as of April 1, 2024	¥ 319	¥ 220,266	¥ 304,033	¥ 1,725	¥ 965,753	¥ 198,613	¥1,164,366
Net income (loss)	—	—	—	—	(6,527)	(13,758)	(20,285)
Other comprehensive income	(98)	(27,830)	(43,045)	(1,725)	(44,770)	(5,377)	(50,147)
Total comprehensive income	(98)	(27,830)	(43,045)	(1,725)	(51,297)	(19,135)	(70,432)
Issuance of new shares	—	—	—	—	240	—	240
Purchase of treasury shares	—	—	—	—	(3)	—	(3)
Disposal of treasury shares	—	—	—	—	0	—	0
Dividends	—	—	—	—	(4,908)	(2,797)	(7,705)
Changes resulting from loss of control of subsidiaries	—	—	—	—	—	28	28
Changes in interest due to transactions with non-controlling interests	—	—	—	—	(35)	35	—
Transfer from other components of equity to retained earnings	—	—	(34,603)	—	—	—	—
Transfer to other comprehensive income associated with assets held for sale	—	(150)	(150)	150	—	—	—
Total transactions with owners	—	(150)	(34,753)	150	(4,706)	(2,734)	(7,440)
Balance as of September 30, 2024	¥ 221	¥ 192,286	¥ 226,235	¥ 150	¥ 909,751	¥ 176,744	¥1,086,495

(4) Consolidated Statement of Cash Flows

Second Quarter (Interim Period) ended September 30, 2025 and 2024

Millions of yen	Q2 FY2025	Q2 FY2024
Cash flows from operating activities:		
Income (loss) before taxes	¥ 87,898	¥ (30,539)
Depreciation and amortization	59,974	66,812
Impairment losses	3,299	253
Share of (profit) loss of investments accounted for using the equity method	27,339	(52,934)
Interest and dividend income	(6,138)	(9,140)
Interest expenses	15,628	14,682
Restructuring costs	3,501	11,702
(Gain) loss on sale of property, plant and equipment, and intangible assets	(211)	(10,717)
(Increase) decrease in trade receivables	27,447	60,218
(Increase) decrease in inventories	(26,282)	(28,612)
Increase (decrease) in trade payables	(2,048)	10,406
Increase (decrease) in unearned revenue	(9,380)	(4,661)
Increase (decrease) in provisions	3,349	(1,207)
Others, net	(106,556)	51,653
Subtotal	77,820	77,916
Interest and dividends received	8,902	11,869
Interest paid	(14,147)	(14,513)
Income taxes refund (paid)	(13,422)	2,157
Restructuring costs paid	(1,488)	(13,883)
Net cash provided by (used in) operating activities	57,665	63,546
Cash flows from investing activities:		
Net (increase) decrease in securities	(11,279)	(5,668)
Purchase of property, plant and equipment, and intangible assets	(61,463)	(75,298)
Proceeds from sales of property, plant and equipment, and intangible assets	2,082	13,705
Proceeds from sales of subsidiaries	55,705	4,079
Purchase of other financial assets	(5,618)	(2,062)
Proceeds from sales and redemption of other financial assets	7,339	143,509
Others, net	(3,451)	(3,843)
Net cash provided by (used in) investing activities	(16,685)	74,422
Cash flows from financing activities:		
Net increase (decrease) in short-term borrowings	(34,315)	(65,479)
Net increase (decrease) in commercial paper	(37,000)	(17,000)
Proceeds from long-term borrowings	6,461	72
Repayments of long-term borrowings	(28,232)	(54,633)
Proceeds from issuance of bonds	—	99,161
Redemption of bonds	—	(20,000)
Repayments of finance lease liabilities	(8,693)	(8,972)
Cash dividends paid	(9,841)	(4,934)
Cash dividends paid to non-controlling interests	(1,471)	(2,798)
Others, net	(1,683)	(801)
Net cash provided by (used in) financing activities	(114,774)	(75,384)
Effect of exchange rate changes on cash and cash equivalents	2,941	(7,877)
Increase (decrease) in cash and cash equivalents	(70,853)	54,707
Cash and cash equivalents at the beginning of the year	209,838	217,449
Net increase (decrease) in cash and cash equivalents resulting from transfer to assets held for sale	22,224	1,200
Cash and cash equivalents at the end of the period	¥ 161,209	¥ 273,356

(5) Notes to Consolidated Financial Statements

Going Concern Assumption

Not applicable.

Segment Information

1. Reportable Segments

The reportable segments of the Group refer to business units for which separate financial information is available and that are reviewed regularly at the Board of Directors meeting in order to determine the allocation of management resources and evaluate the business performance of each business unit.

The Group divides its operations into business sectors identified by products and services, which manage manufacturing, sales, and research in an integrated manner. Each business sector is responsible for developing comprehensive domestic and overseas strategies with respect to its products and services, and operates its business activities.

Principally in accordance with the business sectors, the Group consists of the five reportable segments based on its products and services: "Agro & Life Solutions," "ICT & Mobility Solutions," "Advanced Medical Solutions," "Essential & Green Materials," and "Sumitomo Pharma."

The reportable segments were changed effective Q3 FY2024; the segment information for Q2 FY2024 has been reclassified to reflect the change.

The major products and services of each reportable segment are as follows:

Reportable Segment	Major Products and Services
Agro & Life Solutions	Crop protection chemicals, fertilizers, agricultural materials, household insecticides, products for control of infectious diseases, feed additives, etc.
ICT & Mobility Solutions	Optical products, semiconductor processing materials, compound semiconductor materials, touch screen sensor panels, high-purity aluminum and alumina, specialty chemicals, additives, engineering plastics, battery materials, etc.
Advanced Medical Solutions	Contract development and manufacturing organization business for advanced small-molecule drug, oligonucleotides, and regenerative medicine and cell therapy products, etc.
Essential & Green Materials	Synthetic resins, raw materials for synthetic fibers, various industrial chemicals, methyl methacrylate products, synthetic resin processed products, industrial alumina, synthetic rubber, etc.
Sumitomo Pharma	Small molecule pharmaceuticals

2. Reportable Segment Information

The accounting methods for each reportable segment are, in principle, identical to those used in the consolidated financial statements. The segment profit or loss is core operating income, which is calculated from operating income after excluding effects from non-recurring factors.

Inter-segment sales revenue is based on market prices.

Second Quarter (Interim Period) Fiscal Year 2025

Millions of yen	Agro & Life Solutions	ICT & Mobility Solutions	Advanced Medical Solutions	Essential & Green Materials	Sumitomo Pharma	Total	Others (Note 2)	Adjustments (Note 3)	Consolidated
Sales revenue:									
Sales revenues from external customers	¥ 212,971	¥ 283,482	¥ 21,142	¥ 329,144	¥ 226,071	¥1,072,810	¥ 22,584	¥ —	¥ 1,095,394
Inter-segment sales revenues	504	1,453	6,391	2,432	1,051	11,831	24,772	(36,603)	—
Total sales revenue	213,475	284,935	27,533	331,576	227,122	1,084,641	47,356	(36,603)	1,095,394
Segment profit (loss) : core operating income (loss)	¥ 11,227	¥ 33,109	¥ (1,380)	¥ (18,610)	¥ 97,320	¥ 121,666	¥ 3,235	¥ (16,185)	¥ 108,716

Note 1: ¥97,320 million for segment profit (core operating income) in "Sumitomo Pharma" includes ¥49,544 million for gain related to business transfer.

Note 2: "Others" represents businesses such as supplying electrical power and steam, and providing transport and warehousing, which are not included in reportable segments. Due to the sale of the radiopharmaceutical business and other businesses in FY2024, sales revenue decreased compared to Q2 FY2024.

Note 3: ¥(16,185) million for segment profit (loss) in "Adjustments" includes inter-segment elimination of ¥486 million and corporate expenses of ¥(16,671) million unallocated to each reportable segment. Corporate expenses are mainly research and development expenses for company-wide research, which are not treated as attributable to specific reportable segments.

Second Quarter (Interim Period) Fiscal Year 2024

Millions of yen	Agro & Life Solutions	ICT & Mobility Solutions	Advanced Medical Solutions	Essential & Green Materials	Sumitomo Pharma	Total	Others (Note 1)	Adjustments (Note 2)	Consolidated
Sales revenue:									
Sales revenues from external customers	¥ 225,004	¥ 307,460	¥ 26,750	¥ 450,932	¥ 180,400	¥1,190,546	¥ 50,849	¥ —	¥ 1,241,395
Inter-segment sales revenues	830	2,018	5,016	2,823	47	10,734	34,406	(45,140)	—
Total sales revenue	225,834	309,478	31,766	453,755	180,447	1,201,280	85,255	(45,140)	1,241,395
Segment profit (loss) : core operating income (loss)	¥ 14,161	¥ 43,581	¥ 355	¥ (34,759)	¥ 3,040	¥ 26,378	¥ 19,412	¥ (16,314)	¥ 29,476

Note 1: "Others" represented businesses such as radiopharmaceuticals, supplying electrical power and steam, providing services for the design, engineering, and construction management of chemical plants, and providing transport and warehousing, which were not included in reportable segments.

Note 2: ¥(16,314) million for segment profit (loss) in "Adjustments" included inter-segment elimination of ¥26 million and corporate expenses of ¥(16,340) million unallocated to each reportable segment. Corporate expenses were mainly research and development expenses for company-wide research, which were not treated as attributable to specific reportable segments.

Adjustments to income before taxes from core operating income were as follows:

Millions of yen	Q2 FY2025	Q2 FY2024
Core operating income	¥ 108,716	¥ 29,476
Restructuring costs	(3,501)	(11,702)
Impairment losses	(3,299)	(253)
Gains on sales of property, plant and equipment, and intangible assets	211	10,717
Share of profit of investments accounted for using the equity method (non-recurring factors)	—	86,497
Gains on fair value measurement of the residual interest	—	9,449
Others, net	1,558	(2,935)
Operating income	103,685	121,249
Finance income	7,105	12,283
Finance expenses	(22,892)	(164,071)
Income before taxes (loss)	¥ 87,898	¥ (30,539)

Note: Breakdown of share of profit (loss) of investments accounted for using the equity method included in operating income (loss) was as follows:

Millions of yen	Q2 FY2025	Q2 FY2024
Share of profit (loss) of investments accounted for using the equity method	¥ (27,399)	¥ 52,934
Of which resulting from recurring factors	(27,399)	(33,563)
Of which resulting from non-recurring factors	—	86,497

Material Subsequent Events

(Completed the Sale of Class A Ordinary Shares to Saudi Aramco and Subscription to Class B Ordinary Shares Issued by Petro Rabigh)

To improve Petro Rabigh's financial structure and support its turnaround plan, the Company and Saudi Arabian Oil Company (hereinafter, "Saudi Aramco"), entered into a share transfer agreement on August 7, 2024. Under this contract, it was agreed that, of the equity stake of shares (Class A*¹ ordinary shares) it held, the Company would sell approximately 22.5% of its shares to Saudi Aramco, at a sales price of 7 Saudi riyals per share for a total amount of approximately \$702 million. It was also agreed that the Company would contribute the full amount of capital it gains from the sale of its shares to Petro Rabigh, and that Saudi Aramco would also make an additional contribution of the same amount to Petro Rabigh. Furthermore, the Company and Saudi Aramco agreed with Petro Rabigh to implement the capital contribution by subscribing to a new class of Class B*² ordinary shares that would be issued by Petro Rabigh, pursuant to a subscription agreement executed on August 30, 2025.

On October 8, 2025, the sale of Petro Rabigh Class A ordinary shares by the Company to Saudi Aramco has been completed, and on October 21, 2025, both the Company and Saudi Aramco subscribed to the Class B ordinary shares issued by Petro Rabigh.

Through this, in its consolidated financial results for FY2025, the Company expects to record a gain of approximately ¥50.0 billion from the sale of Class A ordinary shares in other operating income (core operating income). In regard to the newly subscribed Class B ordinary shares, due to the establishment of a fixed interval of several years from the issuance of the shares resulting in the determination of a fair value based on accounting standards, the Company anticipates to record a share valuation loss of approximately ¥15.0 billion due to the difference in value from the price paid as a financial cost. As a result, the net gain is expected to be approximately ¥35.0 billion. The above figures are estimates based on currently available information and are not definite.

In accordance with the sale of Class A ordinary shares mentioned above, the Company's equity stake in Petro Rabigh's Class A ordinary shares has decreased from nearly 37.5% to 15%. However, the Company will maintain a significant influence over Petro Rabigh through the temporary assignment of directors, as well as technical and financial support. Therefore, Petro Rabigh will continue to be its affiliated company accounted for by the equity-method.

(Note 1): Class A ordinary shares refer to ordinary shares with voting rights, and as a result of the issuance of the new Class B ordinary shares, the name of the existing ordinary shares was changed to Class A ordinary shares.

(Note 2): Class B ordinary shares have no voting rights, and certain dividends rights are granted at varying rates each year from 2028 onwards.